At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination With Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer
In Brief
A Phase 1 clinical trial evaluating Biospecimen Collection, Brachytherapy, and 10 other interventions for Advanced Cervical Adenocarcinoma and 12 related conditions. Active but no longer recruiting, targeting 21 participants across 17 sites.
Detailed Summary
This phase I trial studies the side effects and best dose of triapine when given with radiation therapy and cisplatin in treating patients with stage IB2-IVA cervical or vaginal cancer. Triapine may stop the growth of cancer cells by blocking an enzyme needed for cell growth. Cisplatin is a drug used in chemotherapy that kills cancer cells by damaging their deoxyribonucleic acid (DNA) and stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Adding triapine to standard treatment with cisplatin and radiation therapy may kill more cancer cells.
Study Details
Timeline
Interventions
Undergo collection of blood samples
Undergo LDR brachytherapy
Given IV
Undergo FDG-PET/CT
Undergo pelvic EBRT
Undergo FDG-PET/CT
Undergo HDR brachytherapy
Undergo IMRT
Undergo MRI
Correlative studies
Undergo FDG-PET/CT
Given IV and PO